SCHEMBL3902148

SCHEMBL3902148

Cc1ccc(Cl)c(C(=O)NC(c2ccccc2)C(C)(C)N(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.44
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ABCB1 P08183 2/20 0.43
ITGB1 P05556 1/20 0.42
ITGA4 P13612 1/20 0.42
GPR139 Q6DWJ6 1/20 0.41
MAPT P10636 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
P2RX7 Q99572 1/20 0.40
RAB9A P51151 2/20 0.40
UTS2R Q9UKP6 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PSMB5 P28074 1/20 0.39
ANO1 Q5XXA6 1/20 0.38
POLB P06746 1/20 0.38
CYP26A1 O43174 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3902998 0.88 POLB (0.50) LMNAALDH1A1SMN1; SMN2ABCB1UTS2R
SCHEMBL3901053 0.86 GPR139 (0.49) LMNAALDH1A1SMN1; SMN2ITGB1ITGA4
SCHEMBL3913612 0.85 UTS2R (0.46) LMNAALDH1A1SMN1; SMN2MAPTRAB9A
SCHEMBL3902992 0.85 TYK2 (0.45) LMNAALDH1A1SMN1; SMN2MAPTP2RX7
SCHEMBL3910586 0.85 CRHR1 (0.46) LMNAALDH1A1SMN1; SMN2ABCB1ITGB1
SCHEMBL3905178 0.82 POLB (0.42) LMNAALDH1A1SMN1; SMN2GPR139MAPT
SCHEMBL3905781 0.82 UTS2R (0.50) LMNAALDH1A1SMN1; SMN2GPR139MAPT
SCHEMBL3905283 0.82 MEN1 (0.49) ALDH1A1GPR139MAPTP2RX7RAB9A
SCHEMBL3907125 0.81 TAS1R3 (0.51) LMNASMN1; SMN2GPR139P2RX7RAB9A
SCHEMBL3903988 0.80 CTSL (0.44) LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP claimed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1838663-B1 GLYCINE TRANSPORT INHIBITORS GLAXO GROUP LTD (GB) 2009-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270510-A1 GLYCINE TRANSPORT INHIBITORS SLC18A2, SLC6A5, SLC1A2 LMNA 4455/4885ALDH1A1 1358/4885SMN1; SMN2 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.